| 2004 |
- Apr.
- Incorporated
- Nov.
- Series A round (first tranche), $ 0.9 million
|
|---|
| 2005 |
- Jul.
- Series A round (second tranche), $ 1.0 million
- Oct.
- Series B-1 round, $ 1.1 million
|
| 2006 |
- Feb.
- Series B-2 round, $ 7.5 million
- Mar.
- UMN-03: license agreement with Crucell and DSM Biologics
- Jun.
- Renamed Tokyo office as Tokyo head office
- Jul.
- Relocation of Tokyo head office
- Aug.
- UMN-05: license agreement with Protein Sciences Corporation
- Oct.
- Establishment of Akita laboratory
- Nov.
- Establishment of US office
- Nov.
- UMN-03: Biopharmaceutical Manufacturing Agreement with DSM Biologics
|
| 2007 |
- Feb.
- Series C round, $ 18.9 million
|
| 2008 |
- Apr.
- UMN-0501: land in Akita acquired as future site of vaccine manufacturing facility
- Jun.
- UMN-0501: received orphan drug designation by the Japanese Ministry of Health, Labour and Welfare
- UMN-0501: initiation of phase I/II trials
- Aug.
- UMN-0501: preparations for construction of UMN Pharma's vaccine manufacturing facility in Akita
- Dec.
- Relocated Tokyo head office to Yokohama and named as Yokohama Head office
|
2009 |
- Jul.
- Establishment of Yokohama laboratory
- Oct.
- UMN0501: initiation of phase II traial
|
2010 |
- Jan.
- Formed partnership with IHI corporation
- Api.
- Formed partnership with API Co., Ltd.
- May
- Establishment of UNIGEN Inc.
- Jul.
- Adopted for the national project for development and manufacturing of "pandemic" influenza vaccine.
- Aug.
- Formed partnership with Astellas Pharma Inc.
|
